Screener
Jazz Pharmaceuticals JAZZ Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Other non-current liabilities | 161.5 | 124.4 |
| Commitments and contingencies (Note 10) | ||
| Shareholders’ equity: | ||
| Ordinary shares | — | — |
| Non-voting euro deferred shares | 0.1 | 0.1 |
| Capital redemption reserve | 0.5 | 0.5 |
| Additional paid-in capital | 4,243.5 | 4,240.5 |
| Accumulated other comprehensive loss | (651.0) | (568.6) |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's common stock?
- Jazz Pharmaceuticals (JAZZ) reported common stock of $0 in Q1 2026.
- How has Jazz Pharmaceuticals's common stock changed year-over-year?
- Jazz Pharmaceuticals's common stock decreased by 100.0% year-over-year, from $6K to $0.
- What is the long-term trend for Jazz Pharmaceuticals's common stock?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's common stock has grown at a -100.0% compound annual growth rate (CAGR), from $6K to $0.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Jazz Pharmaceuticals's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude